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Abstract
Rationale Temporomandibular disorder (TMD) has been
the most common contraindication for mandibular advance-
ment device (MAD) as a treatment for obstructive sleep
apnea syndrome (OSAS). Exercising the mandible is a
recommended form of therapy for TMD.
Objectives To assess the efficacy of mandibular exercises in
the control of pain, changes of quality of life and to assess
the impact of MAD compliance in OSAS patients with
previously diagnosed TMD.
Methods A blind, randomized, and controlled trial was
used to evaluate 29 OSAS patients with TMDs were
divided in two groups: the exercise support therapy (ST)
and placebo therapy (PT), who were evaluated prior to and
120 days after MAD treatment. Treatment outcomes were
measured using the Fletcher and Luckett sleep question-
naire, Epworth sleepiness scale, SF-36 inventory of quality
of life, polysomnography, diary of MAD usage, and the
research diagnostic criteria for TMD.
Measurements and main results ST group showed signifi-
cant improvement in their sleep quality and life quality
when compared to the PT group (p<0.05). Higher number
of patients with persistent pain was observed in the PT
group (p=0.01). There was a reduction of pain intensity in
the ST group, but not in the PT group (p<0.05). Higher
MAD compliance was observed in the ST group (p<0.05).
Conclusions Mandibular exercises enable patients with
TMD to use MAD; exercises were found to be effective
in reducing pain and increasing MAD compliance and
produced a significant improvement in the quality of life
and quality of sleep.
Keywords Obstructive sleep apnea syndrome .Mandibular
advancement device . Oral appliance . Temporomandibular
disorders .Mandibular exercises
Introduction
A mandibular advancement device (MAD) is an effective
treatment for obstructive sleep apnea syndrome (OSAS) [1,
2]; in addition, it is a noninvasive modality that is reversible
and easy to build. It is widely recommended as a treatment
for snoring and for mild and moderate OSAS [3, 4]. Such
devices are also recommended for mild and moderate
OSAS patients who have not responded to continuous
positive airway pressure therapy (CPAP), who are not
appropriate candidates for CPAP, or whose previous
attempts to use the CPAP failed [5]. It has been widely
described that the use of MAD may have several short-term
side effects, such as excessive salivation, dry mouth, tooth
discomfort, pain in the soft tissue within the mouth, and
pain or discomfort in the masticatory muscles and/or
temporomandibular joints [6–8]. Pain originating either
from the masticatory muscles or the temporomandibular
joint (TMJ) is referred as a temporomandibular disorder
P. A. Cunali (*)
Department of Dentistry, Universidade Federal do Parana,
Rua Cel. Napoleao Marcondes Franca, 360,
80.040-270 Curitiba, PR, Brazil
e-mail: pacunali@onda.com.br
P. A. Cunali :C. D. Santos :N. Y. Valdrichi : L. S. Nascimento :
C. Dal-Fabbro : S. Tufik : L. R. A. Bittencourt
Sleep Medicine and Biology Discipline, Psichobiology
Department, Universidade Federal Sao Paulo,
St. Paul, SP, Brazil
F. R. Almeida
Department of Oral Health Sciences,
University of British Columbia,
Vancouver, Canada
Sleep Breath (2011) 15:717–727
DOI 10.1007/s11325-010-0428-2
(TMD); this pain may be one of the main reasons for poor
compliance or abandonment MAD treatment [9–14]. TMD
patients most frequently report pain or discomfort in the
region of the face. TMD pain can be exacerbated by
mandibular function, resulting in limited mouth opening.
The condition may produce noise from the temporoman-
dibular joint, headaches, and alterations of sleep quality
[15–18]. For pain control and recovery of mandibular
function, noninvasive and reversible modalities of treatment
are the first choices of treatment [18, 19]. Yet another
noteworthy issue is the reduced quality of life endured by
with TMD pain [20, 21] which is also seen in OSAS
patients. Mandibular exercises, known as support therapy
(ST), are used as a treatment modality for TMD. ST is
widely accepted by patients and is efficient in the
management of muscular and joint dysfunction [22–28].
It is noteworthy that in studies of MAD therapy, different
diagnostic criteria have been used to evaluate TMD pain
[6–10] and various authors have contraindicated the MAD
when any sign of TMD was present [10]. Others have
reported noncompliance or suspension of the MAD usage
because of the development of TMD related to MAD usage
[9–14].
However, to our knowledge, there are no studies which
did simultaneously assess therapies controlling TMD pain
and MAD treatment. The purpose of this study was to
assess the efficacy of support therapy (ST) in the reduction
of pain, improvement in the quality of life, and compliance
to MAD treatment in OSAS patients with TMD pain.
Methods
Study population
Adult patients diagnosed with mild and moderate OSAS
[29], with TMD diagnosed by the Research Diagnostic
Criteria (RDC/TMD) [30] adapted and translated to
Portuguese [31, 32] and referred for MAD treatment, were
assessed in the sleep ambulatory unit of Universidade
Federal de Sao Paulo (UNIFESP), Brazil. This experimen-
tal investigation had the approval of the Ethics in Research
Board of the UNIFESP. The inclusion criteria was adopted
for the following indication of MAD described in the
literature [4]: age between 18 and 60 years, apnea–
hypopnea index (AHI) over 5 and under 30, and body
mass index (BMI) less than or equal to 30 kg/m2. Both
genders were included. Patients, who presented fewer than
10 teeth per arch, active periodontal disease, a need of
overall dental treatment, a mandible protrusion less than
5 mm, limited mouth opening, use of alcohol, drugs or
hypnotic substances, and sleep disturbances other than
OSAS with or without previous treatment for OSAS, were
excluded. As cervical myofascial pain can refer pain to the
face, patients with cervical myofascial pain were not
included in this study.
Study design
This study was a double-blind, randomized, and controlled
trial in which patients were distributed into ST and placebo
therapy (PT) groups.
To ensure patients were blinded to the study, both
therapies were explained to the patients as being effective
therapies. The investigator who was blinded to the
randomization has only applied all study instruments of
evaluation such as the RDC, while a second investigator
did the randomization and was responsible for explaining
the exercises to the patients. Patients were evaluated at the
start of the protocol and after 120 days, according to the
experimental design described in Fig. 1. Sleep evaluation
was assessed by polysomnography and by the Flecher and
Luckett questionnaire [33]. Sleepiness was measured by the
Epworth sleepiness scale (ESS) [34], and the quality of life
was assessed by the quality of life inventory (SF-36) [35].
TMD was evaluated by the investigator (PAC) throughout
the study, who was also responsible for advancing and
adjusting the appliance. The presence and type (persistent
or recurring) of TMD pain was assessed after the first week
of MAD use, in the week when MAD advancement reached
two-thirds of maximum mandible protrusion, and in the
week when it reached maximum protrusion. Intensity of
pain was assessed prior to and after treatment. Compliance
to the treatment was registered 1 week after insertion and
after final titration of the MAD by sleep log book. This
book of sleep show that the use of MAD throughout the
night, part of the night, or when the patient did not using
the MAD. These data were also collected by the second
investigator blind while the principal investigator (PAC).
The MAD appliance used is the Brazilian repositioning
device (BRD®), an adjustable device, made in a specialized
laboratory, developed at UNIFESP (Fig. 2a and b). The
appliance was inserted at 50% of the maximum mandible
protrusion advancement; patients were instructed to return
for reevaluation every month and to advance the appliance
0.5 mm/week. This advancement was monitored until the
maximum mandible protrusion was achieved.
Outcome measures
Questionnaires
The Fletcher and Luckett [33] questionnaire consists of
questions about sleep, snoring, nocturnal apnea, and
daytime somnolence. This questionnaire classifies the
answers as never (0), rarely (1), occasionally (2), and often
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(3). Daytime somnolence was evaluated by the Epworth
sleepiness scale [34]. These questionnaires were use to
quantify the sleep complaints of patients. To assess patient’s
quality of life, we used the quality of life inventory (SF-36)
[35] which refers to the subjective quality of life in day-by-
day activities, work, pain, and other activities. All three
questionnaires were used prior to MAD treatment and after
120 days of the treatment.
TMD diagnostic
We employed the “Research Diagnostic Criteria for
Temporomandibular Disorders” (RDC/TMD) [30], a tool
developed to quantify and qualify signs and symptoms of
TMD, to classify TMD. This questionnaire, adapted to
Portuguese, has been used previously [31, 32]. It evaluates
the presence of pain in the facial region and in the TMJ in
the previous 30 days, especially during mandibular func-
tion. All patients were asked to fill out the protocol to score
their chronic TMD pain; clinical exams for classification
and confirmation of TMD were carried out according to the
clinical examination for the RDC/TMD. Three sites of pain
in the masticatory muscles and/or in TMJ, in the clinic
evaluation, coinciding with the same sites of pain complaint
by the patient determined the clinical diagnosis [30]. The
RDC/TMD was applied before treatment and in the week
during which the patients completed 120 days of treatment.
Polysomnography
Polysomnography, used for diagnosis and treatment follow-
up, consisted of the computerized system Sonolab Meditron
(version 2003.a). Surface electrodes were used to record
electroencephalographs (EEG; C3-A2, C4-A1, O2-A1, O1-
A2); submentonian and tibial electromyograph recordings
(EMG); bilateral electrooculograms (EOG); and electro-
cardiographs (ECG-modified derivation V1). Breathing was
monitored with a nasal cannula, in which air flow is gauged
by pressure transduction, and oral flow was monitored with
a thermal sensor. Thoracic and abdominal movements were
Fig. 2 Brazilian repositioning device (BRD®)




















N = 2 patients did not meet 
inclusion criteria
-Chronic Muscle Disease  (1)
-Delayed Sleep Syndrome (1)



































Fig. 1 Model study design. Abbreviations: PSG Polysomnography,
F&L Fletcher and Lucket questionnaire, ESS Epworth sleepiness
scale, SF36 quality of life inventory (SF-36), RDC Research
diagnostic criteria for temporomandibular disorders, MAD mandibular
advancement device
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measured with noncalibrated pletismography. Measure-
ments of oxygen saturation were collected from a wrist
oxymetry device (Nellcor). The position used for the
recordings, lying down, allowed the placement of a sensor
over the sternum bone to define body position, and an
attached tracheal microphone allowed recording of snoring.
Staging was made according to the directives set forth by
Rechtschaffen and Kales [36], and respiratory events were
scored following the criteria adopted by the American
Academy of Sleep Medicine (AASM) board [37]. Awaken-
ings were scored by the criteria of the American Sleep
Disorders Association (ASDA) [38].
Support therapy
Patients were blind to their assigned type of therapy. ST
consisted of coordinated exercises to stretch the mandibular
muscles, and it was adopted to control pain as well as to
restore movement otherwise hampered by TMD pain. For
coordinated movements, patients were instructed to perform
sequences of exercises by controlled mouth opening. This
was achieved by maintaining the tongue in contact with the
palate, followed by a sequence of lateral left–right
movement of the mandible against light-hand resistance.
This type of movement was used with the intent to exercise
the lateral pterygoid muscles and the TMJ (Fig. 3a, b, and
c). For stretching, we used the movement of opening the
mouth against light resistance of the hand, followed by a
maximum opening of the mouth assisted by the fingers,
with the intent of stretching the temporal and masseter
muscles (Fig. 2d and e). Patients were instructed to exercise
twice a day, in three sets of five repetitions of each
movement, prior to and after use of the MAD. These
mandibular exercises, adopted as ST, have proven to be
efficient and effective in the treatment of TMD [19]. The
patients were highly reinforced to do the exercises on a
regular basis, but we could not be sure if patients had
followed our recommendations.
Placebo therapy
PT consisted of two different types of assisted cervical
movement. At first, the patient was instructed to rotate the
head left and right (Fig. 4a and b) and then to tilt the head
to the each side, recovering the vertical position against the
resistance of the hand placed contralaterally (Fig. 4c and d).
This type of exercise was chosen because patients had no
cervical myofascial pain (muscular cervicalgia), a condition
that could point to pain in the face and mimic TMD pain
[39]. Patients in the PT group were instructed to perform
three sets of five repetitions for each movement, twice a
day, prior and subsequent to use of the MAD; this is the
same frequency used for the ST group. Although these
exercises are indicated for myofascial cervical pain, like we
said in the description of study population, patients with
cervical myofascial pain were not included in this study.
Treatment outcome
The efficacy of MAD therapy was measured by the Fletcher
and Luckett questionnaire, ESS, and polysomnography
(PSG). The efficacy of ST in reducing pain intensity was
determined by comparing the intensity of pain, in both ST
and PT groups at baseline settings and after 120 days of
treatment, by the RDC/TMD. We also assessed the
occurrence of TMD pain, which was deemed persistent
when there was pain at the morning MAD removal and
during mastication, preventing the subject from using the
MAD that day. When pain or discomfort was reported only
during removal of the MAD, without compromising its use
or mastication, it was considered recurrent pain.
Changes in quality of life in both groups were
determined by comparing the baseline and end-of-protocol
results of the SF-36 test. In order to determine what
influence ST had in MAD compliance, log books of MAD
use of ST adhesion were maintained by the patients.
Statistical analyses
Results are presented means and standard errors. For
quantitative comparisons between groups, the Student’s t
test for independent samples, or the intra-group Student’s t
test for dependent variables, was used. The Chi-squared test
was used for the categorical data. For statistical calcula-
tions, the software Statistic® 6.0 was used, and the value of
p=0.05 was considered as significant.
Results
A total of 45 (52% of 87 patients) with mild to moderate
cases of OSAS and referred for MAD therapy presented
signs or symptoms of TMD pain. Two patients were
excluded by the inclusion criteria, and 11 never returned
for the initial assessment. Thus, 32 patients were selected
for randomization; 29 completed the protocol.
Comparisons were made between the 14 patients who
either did not finish (n=3) or did not accept to participate in
the study (n=11) and the 29 patients who completed the
protocol. There was no statistical significance between
these groups with regard to age (44.5±10.7×49.7±
9.8 years), BMI (25.2±3.8× 25.9±4.1 kg/m2) or AHI
(13.7 5.25×16.5 4.1;).
At baseline, none of the groups presented any statisti-
cally significant differences, except that the PT group was
on average younger (Table 1).
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The Fletcher and Luckett Sleep questionnaire showed
significant changes, related to treatment, only in the ST
group (Table 2). Comparison of the SF-36 before and after
MAD titration showed a significant improvement in a
higher number of quality of life domains in ST group, as
compared to PT group (in 5 of the 8 domains in the ST
group, and in three of the eight domains for the PT group).
Differences were significant in domains related to pain
(pain, general health) and psychoemotional aspects (limita-
tion by emotional and mental health; Table 2). We found no
difference in polysomnographic parameters between groups
at baseline (Table 1); ST and PT groups both showed a
significant reduction in their AHIs with the MAD. There
was no difference between groups in terms of AHI
improvement, but only the ST group presented a significant
alteration in the minimum oxygen saturation parameter
Fig. 4 Placebo therapy exercises used with different kinds of assisted cervical movements. First the patient was instructed to rotate the head to the
left and to the right sides (a and b), and second to tilt the head sideways forcing the head to the upright position against hand resistance (c and d)
Fig. 3 ST exercises used for coordination and stretching, with the
goal to restore the movements function and control pain. For
coordination, movements of opening and closing the mouth with
tongue limitation (a), and lateral movements against mild hand
resistance were directed to the lateral pterygoide muscles and
temporomandibular joints (b and c); For stretching, the movement of
opening the mouth against hand resistance (d), and the forced assisted
movement of widely opening the mouth, forced by fingers (e), gave
stretching to temporal and masseter muscles
Sleep Breath (2011) 15:717–727 721
(Table 2). There was no significant difference in the type of
complaints of TMD pain in the first week (8 of 15 and 8 of
14 patients in the ST and PT groups, respectively). At two-
thirds of the maximum MAD advancement, there was a
greater number of patients with persistent pain in the PT
group (14 patients) compared to the ST group (three
patients). This condition remained for the maximum
advancement setting, when a higher number of complaints
concerning persistent pain was observed in PT group (ten
patients) compared to ST group (four patients; Fig. 5).
By the criteria of the RDC/TMD, the intensity of pain
decreased between the baseline and the final condition of
the treatment in the ST group, whereas in the PT group,
pain was slightly increased, but without significance
(Fig. 6).
Compliance to the MAD was similar between groups
during the first week. After advancement of the MAD,
greater compliance was observed in the ST group (Fig. 7).
Discussion
This is the first study to assess an ST for TMD pain control
in patients who undergo MAD therapy and who have been
diagnosed with TMD by RDC/TMD prior to MAD
treatment. Patients in the ST group reported less pain,
adhered better to MAD therapy, and experienced significant
improvements in their quality of life and sleep as compared
to patients in the placebo group (PT).
The MAD therapy in the present study resulted in a
significant improvement in AHI and a decrease in the
number of micro-arousals, regardless of the therapy
adopted (ST or PT). The improvements achieved with the
use of the MAD confirm the well-established literature
demonstrating the efficacy of MAD therapy [5, 11, 14].
The quality of life and quality of sleep in OSAS patients
are compromised, and according to some studies, this
condition can be improved by MAD treatment [40, 41]. In
the present investigation, the sleep complaints assessed by
the Fletcher and Luckett questionnaire [33] were reduced
only in the ST group. We also found a significant
improvement in, and in a higher number of, quality of life
domains in the ST group compared with the PT group.
Such differences were represented by domains related to
pain (pain, general health) and psychoemotional aspects
(limitation by emotional and mental health). Although some
improvement was expected in both groups after the same
treatment was offered to the ST and PT groups, MAD
treatment, we hypothesize that persistent pain could be
related to the worsening of the quality of sleep. We
observed that, independent of group (PT or ST), the
excessive daytime sleepiness measured with Epworth
sleepiness scale remained high after the treatment with the
MAD. Although a significant change in sleepiness after
MAD usage has been shown [6, 11, 12, 42], there are other
studies that, in agreement with ours, did not find a
significant change [1, 43]. The ESS is a subjective
measurement tool, and it does not always correlate well
Placebo therapy Support therapy p Values
Age 44±12 53±9 0.032
BMI (kg/m2) 26±4 26±4 NS
Gender (M/F) 5/9 4/11 NS
ESS 12±6 14±6 NS
FLQ 0.4±0.2 0.5±0.2 NS
SF36 FC 60±16 70±19 NS
SF36 LPhA 32±34 54±45 NS
SF36 PAIN 44±21 37±20 NS
SF36 GSH 56±24 54±21 NS
SF36 V 32±15 39±22 NS
SF36 SA 62±30 46±25 NS
SF36 LEA 40±40 43±44 NS
SF36 M 49±17 50±15 NS
Sleep efficiency (%) 89±8 87±6 NS
Stages 3 and 4 (%) 19±5 17±6 NS
REM (%) 20±5 19±5 NS
Arousals (/h) 15±7 16±7 NS
AHI (/h) 18±10 16±8 NS
MinSatO2 (%) 86±4 86±4 NS
Table 1 Baseline demograph-
ics, sleep, and quality of life
questionnaires and polysomno-
graphic data between ST and PT
groups
Differences are defined as p>
0.05
ST Support therapy, PT placebo
therapy, BMI body mass index,
ESS Epworth sleepiness scale,
AHI apnea–hypopnea index,
MinSatO2 minimum oxygen sat-
uration, FLQ Fletcher and Luck-
ett questionnaire, SF36 SF 36
inventory for quality of life, FC
functional capacity, LPhA limit
by physical aspects, PAIN pain,
GSH general state of health, V
vitality, SA social aspect, LEA
limit by emotional aspects, M
mental health, NS Not signifi-
cant, test “t” for independent
samples
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with objective measures of excessive sleepiness, such as the
multiple latency sleep test or the maintenance of vigil test
[44]. Because this study did not apply objective measures
of sleepiness, we hesitate to conclude that the use of the
MAD did not reduce patients’ sleepiness. Another possi-
bility of EDS persistency could be a chronic pain condition
with long period of sleep fragmentation leading to
alteration in the awake–sleep brain system.
The contraindications of MAD treatment in TMD
patients probably originated due to side effects like pain
in the TMJ and masticatory muscles cause by MAD use [9,
10, 45]. Such exclusions, however, have been made in the
absence of reproducible, systematic diagnostic criteria for
TMD. As a result of the present study, we believe that the
contraindication of MAD for patients with TMD is not
based on proven results, and patients with TMD are still



















Fig. 6 Average of the intensity of pain caused by TMD at the baseline
and final MAD position in placebo therapy (PT) and support therapy

























Fig. 5 Number of patients with persistent and temporary pain caused
by TMD at baseline, two-thirds and maximal advancement of the
MAD in placebo therapy group (PT) and support therapy (ST) groups
(Chi-squared test). *p<0.05
Table 2 Demographics, sleep, and quality of life questionnaires and polysomnographic data between ST and PT groups in baseline and after
MAD treatment
Placebo therapy Support therapy
Baseline With MAD Baseline With MAD
BMI (kg/m2) 26±4 26±4 26±4 27±4
ESS 12±6 11±6 14±6 13±7
FLQ 0.4±0.2 0.4±0.1 0.5±0.2* 0.4±0.1**
SF36 FC 66±28 66±28 70±19 70±29
SF36 LPhA 32±34 54±40* 54±45 73±30
SF36 PAIN 44±21 51±26 37±20 55±22**
SF36 GSH 54±24 59±20 54±21** 67±23**
SF36 V 31±15 44±19* 39±22** 51±19**
SF36 SA 58±29* 76±28* 46±23 66±32
SF36 LEA 40±40 59±44 43±44* 71±35**
SF36 M 48±17 57±22 50±16* 65±22**
MAI (#h sleep) 15±7 8±3* 16±7 11±6**
AHI (/h sleep) 18±10 7±5** 16±8 9±7 **
MinSatO2 (%) 86±4* 88±3* 86±4 87±5
BMI Body mass index, ESS Epworth sleepiness scale, MAI micro-arousal index, AHI apnea–hypopnea index, MinSatO2 minimum oxygen
saturation, FLQ Fletcher and Luckett questionnaire, SF36 SF 36 inventory for quality of life, FC functional capacity, LPhA limitation due to
physical aspects, GSH general state of health, V vitality, SA social aspect, LEA limitation by emotional aspects, M mental health, MAD mandibular
advancement device
* p<0.05 difference between baseline and at maximum mandibular advancement in PT group
** p<0.05 difference between baseline and at maximum mandibular advancement in ST group
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In our previous investigation [46], the prevalence of
TMD was high (52%) in the OSAS population referred for
MAD therapy. Of the individuals who showed TMD¸ 90%
had myofascial masticatory muscles pain, and in 65% of
those, joint pain was present. In 75% of the patients, the
impact of TMD pain was of low intensity and low
disability. Petit and colleagues [10] reported an active
TMJ disorder was present in only 2% of patients.
The prevalence of side effects related to TMJ or masseter
muscle pain was very different between studies [13, 40,
47]. As neither the degree of involvement nor the specificity
of the TMD was determined, mild and severe cases were
almost certainly lumped and assessed as one entity. The
percentages of such side effects vary and can even be
justified by the absence of a validated methodology with
previous assessment of TMD [6–8]. Still, the authors did not
use standardized classification criteria for the diagnosis of
TMD prior to the treatment; therefore, it is possible that
some of those 11 patients had TMD prior to the treatment.
In 2001, Fritsch and collaborators [7] assessed side effects
of the MAD in 22 individuals; mandibular pain was found
to occur in nine patients (41%), and either stiffness or pain
in the masseter was found in eight patients (36%). Prior
systematic TMD evaluation was not assessed, similar to
many other studies of MAD side effects [11–14]. This lack
of diagnostic criteria for assessment, in our opinion, is
responsible for such different findings. In the present
investigation, the use of the RDC/TMD as a diagnostic
instrument for TMD enabled us to assess the presence of
TMD in OSAS patients prior to MAD treatment. Likewise,
until the present report, there were no studies using a
systematic protocol to evaluate TMD.
Yet another relevant issue is that none of the studies that
assessed TMD as a side effect of MAD addressed alternative
methods to minimize those effects and thus enabled
continuation of the treatment [6–8]. Mandibular exercises,
whether associated to other noninvasive treatment modali-
ties (counseling and occlusion plates, for example) or not,
have been used with satisfactory results in the control of
pain caused by TMD. In those modalities, the observation
period of patients submitted to exercises varied according to
the protocol, but in general, good results were produced
after 3 months [20–25]. In randomized controlled studies,
mandibular exercises and counseling were compared to
isolated counseling for the treatment of myofascial pain. The
studies showed better results with the mandibular exercises;
therefore, they suggest exercise therapy as a first choice
intervention in muscular TMD [20, 21]. Also, passive
mandibular exercises, used for the treatment of joint disc
displacement with [22] and without reduction [23], showed
a significant reduction of pain after 6 months. Mandibular
exercises also improve significantly joint sounds, compared
to a control group [25]. Ueda and collaborators [48] used
mandibular exercises combined with a MAD and found that
this type of therapy did improve occlusal contact area and
bite force. The authors related those findings to tooth
movement and did not evaluate systematically the presence
or absence of TMD. The current study is, to our knowledge,
the first to use mandibular exercises with MAD therapy for
patients with TMD and OSAS. Similarly to previous
studies, we also found that mandibular exercises produced
a significant improvement in TMD. Differently than those
studies, our patients used the MAD therapy at night and the
ST during the day.
The amount of mandibular protrusion prescribed as
necessary for the treatment of OSAS varies between half
and maximum mandibular advancement. The results col-
lected herein show that when the MAD is positioned at
two-thirds of the maximum mandibular advancement, the
ST group presented less pain when compared to the PT
group (three vs. nine patients, respectively), and the same
distribution of pain prevalence was seen at maximum
mandibular protrusion (four vs. ten, respectively). Accord-
ing to the RDC/TMD criteria, pain intensity decreased from
pre-treatment to final mandibular protrusion only in the ST
group. Contrarily, the PT group showed a slight increase in
pain at the end of treatment. It is important to notice that the
amount of mandibular protrusion did not differ between the
groups, which allow us to infer that the amount of
mandibular protrusion had no influence in the final results.
This data confirms the efficacy of ST in OSAS/TMD
patients treated with a MAD. As yet, the available literature
does not report that exercise aids the treatment of OSAS for
patients with concomitant TMD.
Important studies have assessed pain as a factor for poor
compliance to MAD; these studies showed that in a period
of 3–7 months of follow-up, compliance rates vary from












































Fig. 7 MAD compliance at various phases of the study based on
diaries and presented as percentage of hours by night used in the
previous month in placebo therapy (PT) and support therapy (ST)
groups (test “t” for independent and dependent samples)
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therapy in this investigation, no significant difference was
found between the groups in the baseline conditions (76%
vs. 88% in the PT and ST groups, respectively). However,
after MAD advancement, higher adherence in the ST group
was observed (68% vs. 92% for PT and ST, respectively). It
can thus be inferred that mandible exercises most likely leads
to higher compliance to the use of a MAD in OSAS patients.
Although the results of the current investigation are
significant and might change indications and add exercises
to the management of patients in MAD therapy, clinical trials
poses challenges and some limitations to the study must be
taken into account. First, the number of patients was small,
and the RDC/TMD diagnosis was carried out by only one
examiner. Larger samples are necessary, and ideally, two
investigators would evaluate intra- and inter-observer biases.
Second, because of the nature of the intervention, the
patients would have been aware of the study allocation and
may have inadvertently unblended the investigators. As the
main outcome measures in this study were subjective, the
potential for investigator bias is an important consideration.
Third, because there is no objective instrument to assessMAD
compliance, we have recorded compliance subjectively by
means of a diary, which has been shown to overestimate the
hours of use. Another limitation of the present study was that
exercises were not supervised; adherence to the exercise
protocol was also recorded only by means of a diary. The
follow-up period of 120 days is relatively short and thus, it is
not possible to draw conclusion about the long-term effec-
tiveness of intervention. Finally, the MAD advancement
protocol used in the present study does not match the
traditional protocol. Our patients started at 50% advancement,
instead of the 60% to 75% advancements stated in the
literature.We believe that this was not important to our results,
as we had a controlled placebo group. The exclusion of
patients with mandibular protrusion of less than 5 mm or
limited mouth opening would have excluded patients with
more significant forms of TMD and limits the generalizability
of the results. In addition, this study did not recruit obese
patients or those with severe OSAS further limiting the
generalizability of the findings for these patients. However,
further studies are necessary to evaluate the ST under
traditional advancement protocols.
The fact of MAD being contraindicated in presence of
TMD is still controversial. There is one paper in the literature
[49] stating short-term benefits of MAD on bruxism, which
is commonly associated with TMD. Despite of this, to our
knowledge, most papers available in Pubmed, have stated
that moderate to severe TMJ problems or an inadequate
protrusive ability may be contraindications to MAD therapy
[3, 10, 45]. These conflicting positions might be related to
the term TMDs, which we understand is not specific.
Although, in this research field the RDC criteria are until
now, in our opinion, the best research tool available. Still, we
believe that once better assessments tools are available
further studies are necessary. The fact that we have evaluated
only one type of MAD also configures a limitation of this
study, and therefore similar studies with most commonly
used appliances such as Klearway, Herbist, and PM
Positioner are necessary for our data to be generalized.
Despite some limitations, the results of the present study
allow us to suggest that OSAS patients who are referred for
MAD therapy require a specific assessment of TMD. Our
results also demonstrate that the contraindication of MAD for
the treatment of OSAS should be reexamined and that
mandibular exercises, when adopted as ST, can be influential
in decreasing pain and increasing MAD compliance in the
120 days of treatment in this study. Although the positive
result of ST in patients treated in this study, severe functional
limitations for TMD should be evaluated carefully. These
conditions have yet to be primarily treated for TMD.
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